Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: KUC 7483 CL, immediate release tabletDrug: KUC 7483 CL, particulate formulationDrug: KUC 7483 CL, solution formulationDevice: Enterion™ capsule
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02259920
Telmisartan in Mild to Moderate Hypertensive Patients
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Low dose of telmisartanDrug: High dose of telmisartanDrug: Placebo
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 134
- Registration Number
- NCT02260089
Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT02259894
Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 34021 FU2 solutionDrug: PlaceboDrug: BI 34021 FU2 tabletOther: High fat, high calorie breakfast
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT02259842
Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT02260076
Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02259829
Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity
Phase 1
Completed
- Conditions
- Spinal Cord Injuries
- Interventions
- Drug: PlaceboDrug: KUC 7483 CL
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02259751
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02259790
Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BEA 2180 BR infusionDrug: BEA 2180 BR oral
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02258971
Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBP 5371 CL tablet low doseDrug: BIBP 5371 CL tablet high doseDrug: Placebo drinking solutionDrug: BIBP 5371 CL solutionOther: High fat, high caloric breakfastDrug: BIBP 5371 CL tabletDrug: Placebo tablet
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT02256709